THE WORLD reference laboratory for foot and mouth disease (FMD) at Pirbright has won funding of £2million to boost its status as the global centre of expertise on the disease. The Food and Agriculture Organisation of the United Nations (FAO) and the World Organisation for Animal Health (OIE) have recognised the Pirbright lab, part of the UK Biotechnology and Biological Sciences Research Council (BBSRC)-funded Institute for Animal Health.
This news follows the launch of the FAO and OIE global FMD control strategy last week and puts Pirbright at the centre of the first five-year phase of work.
At the launch of the strategy, Dr Jef Hammond, head of the Institute’s World, EU, OIE and national reference laboratories for FMD, presented the global FMD situation to representatives of 100 OIE member countries, including many chief veterinary officers.
He said “The initial phase of the strategy, which includes the funding for our lab, gives us an opportunity on a global scale to implement the measures that we know can work to control FMD. T
“The FAO and OIE are promoting a coordinated approach across the world using effective diagnostics, vaccines and other control measures – many of which were developed here at Pirbright.”
Hammond plans to use the funds to create a dedicated team at Pirbright that will focus on delivering the aims of the global foot and mouth disease control strategy.
The UK suffered a serious foot-and-mouth outbreak in 2001, costing at least £8 billion, but is currently FMD-free.
The disease is endemic in many countries, with global losses estimated at $5 billion per year. The World Bank has suggested a budget of just under $1 billion over five years to fund the initial programme of work.
Dr Bryan Charleston, head of the Livestock Viral Disease Programme at the Institute said “Over the 15 years covered by this strategy and with the funding committed there is a chance to make great strides not only in FMD but to improve veterinary services and control of many livestock diseases across the world.
“Ultimately we will need to have vaccines against FMD that are at least as effective as existing vaccines but are easier to manufacture and handle. At the Institute we are focussed on developing vaccines that can be produced on a large scale without the need for high containment facilities and that are stable at higher temperatures.”
Dr Hammond added: “What a farmer in, say, Rwanda needs is a good, cheap vaccine that is stable without refrigeration and can go straight into his or her cattle to provide lasting protection. We hope that during the lifetime of this initiative we will be in a position to provide just such a vaccine.”